Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

Abstract

Adding abatacept to URD HCT was safe, reduced AGVHD, and improved SGFS. These results suggest that abatacept may substantially improve AGVHD-related transplant outcomes, with a particularly beneficial impact on HLA-mismatched HCT.